AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca highlighted pipeline progress during its quarterly earnings call, but remained on the defensive as analysts questioned two newly disclosed U.S. federal inquiries and the promotion of Marc Dunoyer to CFO, as the Big Pharma struggles with falling sales and profits.